BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 27, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 1, 2003
View Archived Issues
Regeneron Plummets On Early Phase III Results With Axokine
Preliminary results from Regeneron Pharmaceutical Inc.'s Phase III trial with the obesity drug Axokine are being called mixed, but the market's reaction was unambiguous, taking away 56.6 percent of the stock's value.
Read More
Palatin Raises $19M Privately For LeuTech, PT 141 Programs
Read More
Industry, Academia Collaborate To Crack Stubborn Enigma Of HCV's Unswerving Hepatic-Cell Tropism
Read More
UK Office Fines Genzyme Over Practices Related To Cerezyme
Read More
Other News To Note
Read More